2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 4: March 27, 2024 - Targeting Chronic Spontaneous Urticaria: Tips on Management
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, March 27, 2024
8 PM ET / 5 PM PT
Targeting Chronic Spontaneous Urticaria: Tips on Management
This activity is supported by educational grants from Genentech, a member of the Roche Group, Novartis Pharmaceuticals Corporation, and Sanofi and Regeneron Pharmaceuticals.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
March 28, 2024
March 28, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the burden of CSU and potential impacts to patient quality of life
Discuss strategies for optimizing the diagnosis of CSU
Define the role of targeted therapies for the treatment and management of CSU
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Brad Glick, DO, MPH
Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs Campus
Hialeah, FL
Dawn Merritt, DO
Dermatology Residency Program Director
OhioHealth Riverside Hospital
Columbus, OH
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Ownership interest: Top MD stock
Consultant: Abbvie, Arcutis, BMS, Dermavant, Lilly, Novartis, UCB
Speaker's Bureau or Honoraria: Abbvie, Amgen, BMS, Dermavent, LEO, Lilly, Pfizer
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.